ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Broad could receive $125 million in sponsored research agreement with Editas

by Ryan Cross
June 17, 2018 | APPEARED IN VOLUME 96, ISSUE 25

 

The CRISPR gene-editing company Editas Medicine has signed a sponsored research agreement with Broad Institute of MIT and Harvard. The deal stipulates that the institute could receive up to $125 million and Editas will have the first right to license Broad inventions arising from the sponsored research. Editas currently owes Broad two payments totaling $12.5 million. The agreement comes after Broad scientists Feng Zhang and David Liu, who are also cofounders of Editas, launched three new companies this year based on their CRISPR inventions.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment